A case of TAFRO syndrome, a variant of multicentric Castleman’s disease, successfully treated with corticosteroid and cyclosporine A

References

• El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4):497–511.
   PubMed Web of Science ®Google Scholar
• Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16(9):1316–24.
   PubMed Web of Science ®Google Scholar
• Muskardin TW, Peterson BA, Molitor JA. Castleman disease and associated autoimmune disease. Curr Opin Rheumatol. 2012;24(1):76–83.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010;8(7):486–98.
   PubMedGoogle Scholar
• Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16(4):236–46.
   PubMed Web of Science ®Google Scholar
• Dham A, Peterson BA. Castleman disease. Curr Opin Hematol. 2007;14(4):354–9.
   PubMed Web of Science ®Google Scholar
• Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53(1):57–61.
   PubMedGoogle Scholar
• Takai K, Nikkuni K, Momoi A, Nagai K, Igarashi N, Saeki T. Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases. J Clin Exp Hematop. 2013;53(1):63–8.
   PubMedGoogle Scholar
• Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, et al. Clinical features and treatment of multicentric Castleman's disease: a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop. 2013;53(1):69–77.
   PubMedGoogle Scholar
• Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, et al. Japanese variant of multicentric Castleman's disease associated with serositis and thrombocytopenia – a report of two cases: is TAFRO syndrome (Castleman – Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop. 2013;53(1):79–85.
   PubMedGoogle Scholar
• Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, et al. Atypical hyaline vascular-type Castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop. 2013;53(1):87–93.
   PubMedGoogle Scholar
• Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hematop. 2013;53(1):95–9.
   PubMedGoogle Scholar
• Awano N, Inomata M, Sonoda Y, Kondoh K, Ono R, Moriya A, et al. A case of multicentric Castleman's disease of mixed-type, which showed constellation of symptoms, i.e., thrombocytopenia, anasarca, anemia, fever, myelofibrosis, and lymphadenopathy. J Clin Exp Hematop. 2013;53(1):101–5.
   PubMedGoogle Scholar
• Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, et al. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med. 2013;52(13):1503–7.
   PubMed Web of Science ®Google Scholar
• Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, et al. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman’s disease. BMC Pediatr. 2014;14:139.
   PubMed Web of Science ®Google Scholar
• Koduri PR, Parvez M, Kaza S, Pappu P, Anuradha S. Castleman-Kojima disease in a south Asian adolescent. J Clin Exp Hematop. 2014;54(2):163–6.
   PubMedGoogle Scholar
• Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, et al. Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy – a case report. Exp Hematol Oncol. 2015;4(1):3.
   PubMed Web of Science ®Google Scholar
• Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, et al. Durable remission with rituximab in a patient with an unusual variant of Castleman’s disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015;90(11):1091–2.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Usui T, Okada H, Mori I, Yamauchi M, Ikeda T, et al. TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol. 2015. [Epub ahead of print]. doi: 10.3109/14397595.2015.1059982.
   PubMed Web of Science ®Google Scholar
• Tatekawa S, Umemura K, Fukuyama R, Kohno A, Taniwaki M, Kuroda J, Morishita Y. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep. 2015;3(6):472–8.
   PubMed Web of Science ®Google Scholar
• Allegra A, Rotondo F, Russo S, Calabrò L, Maisano V, Bacci F, Musolino C. Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: A rare case report and review of the literature. Blood Cells Mol Dis. 2015;55(3):206–7.
   PubMed Web of Science ®Google Scholar
• Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease, with cyclosporine A: possible pathogenic comtribution of interleukin-2. Tohoku J Exp Med. 2015;236(4):289–95.
   PubMed Web of Science ®Google Scholar